Evidence map›Paper›PMID 35884843›Full record

ArticleBiomedicines2022

Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.

Chih-Cheng Tsao, Hsin-Hung Wu, Ying-Fu Wang, Po-Chien Shen, Wen-Ting Wu, Huang-Yun Chen, Yang-Hong Dai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chih-Cheng TsaoDepartment of Radiation Oncology, Taitung MacKay Memorial Hospital, Taitung 950, Taiwan.
Hsin-Hung WuDepartment of Pulmonary Medicine, Taitung MacKay Memorial Hospital, Taitung 950, Taiwan.
Ying-Fu WangDepartment of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Po-Chien ShenDepartment of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Wen-Ting WuInstitute of Pathology and Parasitology, National Defense Medical Center, Taipei 114, Taiwan.
Huang-Yun ChenCancer and Hospice Care Center, Taitung MacKay Memorial Hospital, Taitung 950, Taiwan.
Yang-Hong DaiDepartment of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Mackay Memorial Hospital · TWTri-Service General Hospital · TWNational Defense Medical Center · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICI) for early-stage non-small cell lung cancer (NSCLC) have been approved to improve outcomes and reduce recurrence. Biomarkers for patient selection are needed. In this paper, we proposed an inflammasome-based risk score (IRS) system for prognosis and prediction of ICI response for early-stage NSCLC. Cox regression analysis was used to identify significant genes (from 141 core inflammasome genes) for overall survival (OS) in a microarray discovery cohort (

Indexed as

CASP-1early-stage NSCLCGSDMDIL18IL1Bimmune checkpoint inhibitorimmunotherapyinflammasomeSLAMF8

Identifiers

PMID35884843
PMCPMC9313462
OpenAlexW4283694167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.